Research Library

The top resource for free research, white papers, reports, case studies, magazines, and eBooks.

Share Your Content with Us
on TradePub.com for readers like you. LEARN MORE
Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies
Request Your Free Webinar Now:

"Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies"

Chimeric antigen receptor T-cell therapy targeting the surface receptor CD19 (CAR19) is a potent treatment option for patients with relapsed or chemotherapy-refractory B-cell malignancies. Unfortunately, cancer continues to progress in a large subset of these patients due to changes in CD19-presentation on the cancer cells.

To eliminate malignant B cells with low CD19 levels, researchers have developed CAR therapies that target the B cell-specific cell surface molecule CD22. While sequential CAR therapy has shown limited success, scientists have now developed a bispecific CAR-T cell that simultaneously targets CD19 and CD22.

This webinar from IsoPlexis discusses recent advances in the development of bispecific CAR-T therapy and critical functional biomarkers for characterizing CAR-T cell product quality.


Offered Free by: Isoplexis
See All Resources from: Isoplexis

Recommended for Professionals Like You: